AVDL - avadel.com Sales Growth YoY (TTM)

Brandmark of Avadel Corp (AVDL)

Avadel Pharmaceuticals (AVDL) is developing the psychoneurology market through its convenient drug Lumryz, although patent litigation and slow insurance coverage are hindering expansion. This TTM annual sales growth chart visualizes this trend, where the 79.70 mark reflects the current state of revenue. Supply stability is maintained through logistics diversification and the creation of warehouse reserves to eliminate drug shortages.

AVDL (Avadel Pharmaceuticals plc) Sales Growth YoY (TTM) history from 02/11/2024 to 02/28/2026

Avadel Corp (AVDL) - metric breakdowns and financial figures

- market value and analyst target forecast:
Analysis of all company metrics:Avadel Pharmaceuticals (AVDL)
Flagship merchandise of Avadel Pharma

Focusing on the US domestic market, Avadel Pharmaceuticals (AVDL) is exposed to risks of raw material supply chain disruptions from Asia, which directly impacts sales volumes. By analyzing this 12-month rolling YoY revenue growth chart, an investor can observe sales dynamics without quarterly distortions or low-base effects, making it possible to distinguish sustainable business scaling from one-off spikes and avoid overpaying for the asset.